Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Inclusion Criteria: * Patients diagnosed with histologically confirmed recurrent ovarian stromal tumor (granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor \[androblastoma\], steroid \[lipid\] cell tumor, gynandroblastoma, unclassified sex cord-stromal tumor, sex cord tumor with annular tubules) * Patients must have measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria * Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each ?target? lesion must be \>= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or \>= 10 mm when measured by spiral CT * Patients must have a Gynecologic Oncology Group (GOG) performance grade of 0, 1, or 2 * Patients of childbearing potential must have a negative pregnancy test and must agree to practice an effective means of birth control * Patients who have met the pre-entry requirements specified * There are no restrictions on prior therapy; however, patients cannot have previously had treatment with bevacizumab * Absolute neutrophil count (ANC) \>= 1,000/?l * Platelets greater than or equal to 75,000/?l * Creatinine =\< 1.5 x institutional upper limit normal (ULN) * Bilirubin =\< 1.5 x ULN * Serum glutamic oxaloacetic transaminase (SGOT) less 2.5 x ULN * Alkaline phosphatase less 2.5 x ULN * Neuropa…